A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients with Immunoglobulin A (IgA) Nephropathy (ARTEMIS-IgAN)

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients with Immunoglobulin A (IgA) Nephropathy (ARTEMIS-IgAN)
Recruiting
18 years - 80 years
All
Phase 3
1 Location

Brief description of study

This study will use a new investigational study drug called OMS721 in people with Immunoglobulin A (IgA) Nephropathy. This kidney disease produces abnormal amounts of a protein called IgA in the kidney that damage the filtering units or glomeruli. Glomeruli are tiny filtering units in the kidney that remove excess fluid and waste (and other toxins) from your blood stream.

Detailed description of study

The purpose of this study is to test the safety and describe the effect of OMS721, an "investigational drug", in people with IgA Nephropathy. "Investigational drug" means that the drug has not been approved for sale in the United States by the U.S. Food and Drug Administration (U.S. FDA) for this purpose.

You are being asked to consider taking part in this study because you have IgA Nephropathy. Researchers want to find out if giving OMS721 investigational drug to people with IgA Nephropathy is safe and tolerable and may help treat your condition.

This is the second time that OMS721 is being studied in people with IgA Nephropathy. In an ongoing study of OMS721 for patients with glomerular nephropathies (kidney diseases), a total of 29 patients have taken part as of 19 February 2019. Nineteen of those patients had IgA Nephropathy. OMS721 is being studied in people with other diseases. As of 19 February 2019, 54 patients have received OMS721 in a study with another disease known as Thrombotic Microangiopathies (TMA). In addition, in two other studies, at least 131 healthy volunteers have received OMS721.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: IgA,IgAN,Immunoglobulin A Nephropathy
  • Age: 18 years - 80 years
  • Gender: All


Updated on 19 Feb 2024. Study ID: 832096

Find a site

Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Message For Non Enrolling By Invitation Trial

Select a study center that’s convenient for you, and get in touch with the study team.